This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies
March 11-14, 2024 | Part of BPI West
Town and Country ResortSan Diego, CA

Mustafa Turkoz
Head of Immunology at Turn Biotechnologies


Mustafa Turkoz obtained his PhD from Washington University in St. Louis, and did his postdocs at Cincinnati Children's Hospital and Stanford University School of Medicine. He has more than 10 years background in immunology and immuno-oncology space, and more than 5 years in adoptive cell and autologous/allogeneic CAR-T therapies. He specializes in T-cell immunotherapy and cellular immunology to understand and utilize immune cell-based therapies in treatment of cancer and some other immunological disorders. Recently, he is focusing on rejuvenation of immune cells using epigenetic reprogramming to enhance efficacy of adoptive cell and CAR-T therapies in the clinic.

Agenda Sessions

  • Transient Epigenetic Reprogramming Enhances CAR-T-cell Proliferation and Tumor Killing